Formulary Watch |

All News - Page 11

FDA Approves First Subcutaneous Infliximab for IBD
FDA Approves First Subcutaneous Infliximab for IBD
FDA Approves First Subcutaneous Infliximab for IBD
October 23, 2023
Zymfentra is a subcutaneous version of infliximab.
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
Phase 3 Trial Shows Significant Weight Loss with Mounjaro
October 20, 2023
Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
KFF: Premiums for Employer-Sponsored Insurance Increased 7% in 2023
October 19, 2023
The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.
Questions Remain about Nonprescription Opill
Questions Remain about Nonprescription Opill
Questions Remain about Nonprescription Opill
October 16, 2023
Whether Opill (norgestrel) truly broadens access to daily contraception will depend on Medicaid coverage, requirements under the ACA and pharmacist prescribing.
Study Explores Connection Between Adherence and Viral Suppression in Patients with HIV
Study Explores Connection Between Adherence and Viral Suppression in Patients with HIV
Study Explores Connection Between Adherence and Viral Suppression in Patients with HIV
October 13, 2023
Researchers identified age and insurance type as significant factors in viral suppression in patient with HIV because of their impact on patient adherence.
PBM Ventegra Adds Yuflyma Biosimilar as Preferred Product
PBM Ventegra Adds Yuflyma Biosimilar as Preferred Product
PBM Ventegra Adds Yuflyma Biosimilar as Preferred Product
October 11, 2023
Yuflyma is on Ventegra’s public and private formulary on parity with the reference product Humira.
Court Ruling Takes Aim at Copay Accumulators
Court Ruling Takes Aim at Copay Accumulators
Court Ruling Takes Aim at Copay Accumulators
October 10, 2023
Insurers and PBMs now have to follow a 2020 rule in which accumulator programs can only be applied to brand name drugs that have generic equivalents available.
Express Scripts Lists Inpefa as Preferred on Medicare Formularies
Express Scripts Lists Inpefa as Preferred on Medicare Formularies
Express Scripts Lists Inpefa as Preferred on Medicare Formularies
October 10, 2023
Inpefa is an inhibitor of both SGLT2 and SGLT1, approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. The wholesale acquisition cost is $598 per month.
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
October 9, 2023
Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.
Analysis: Medication Adherence Positively Impacts RA Patients’ Healthcare Costs and Usage
Analysis: Medication Adherence Positively Impacts RA Patients’ Healthcare Costs and Usage
Analysis: Medication Adherence Positively Impacts RA Patients’ Healthcare Costs and Usage
October 6, 2023
Patients who continued with their rheumatoid arthritis biologic medication tended to spend less on healthcare, had a lower chance of being hospitalized, and had shorter hospital stays.
Drug Price Negotiations: “We Need to Have an Honest Conversation about Drug Costs”
Drug Price Negotiations: “We Need to Have an Honest Conversation about Drug Costs”
Drug Price Negotiations: “We Need to Have an Honest Conversation about Drug Costs”
October 5, 2023
Mark Campbell, Pharm.D., RxBenefits’ senior vice president of clinical solutions, talks about how Medicare’s drug price negotiations could have a ripple effect on pharmaceutical company innovation and prices on the commercial side.
Medicare Drug Price Negotiations to Move Forward
Medicare Drug Price Negotiations to Move Forward
Medicare Drug Price Negotiations to Move Forward
October 4, 2023
ICER has weighed in on two of the 10 drugs selected for negotiations: Eliquis and Xarelto, which are among Medicare Part D’s highest spending drugs.
IRA Impact: Lowered Patient Costs, but Also Higher Utilization Management?
IRA Impact: Lowered Patient Costs, but Also Higher Utilization Management?
IRA Impact: Lowered Patient Costs, but Also Higher Utilization Management?
October 3, 2023
Once Medicare’s negotiated price for prescription drugs goes into effect, payers have more of an incentive to steer patients to lower-cost alternatives.
© 2024 MJH Life Sciences

All rights reserved.